171 related articles for article (PubMed ID: 20633538)
1. RANKL-RANK signaling regulates expression of xenotropic and polytropic virus receptor (XPR1) in osteoclasts.
Sharma P; Patntirapong S; Hann S; Hauschka PV
Biochem Biophys Res Commun; 2010 Aug; 399(2):129-32. PubMed ID: 20633538
[TBL] [Abstract][Full Text] [Related]
2. Expression of the mammalian Xenotropic Polytropic Virus Receptor 1 (XPR1) in tobacco leaves leads to phosphate export.
Wege S; Poirier Y
FEBS Lett; 2014 Jan; 588(3):482-9. PubMed ID: 24374333
[TBL] [Abstract][Full Text] [Related]
3. Xenotropic and polytropic retrovirus receptor 1 (XPR1) promotes progression of tongue squamous cell carcinoma (TSCC) via activation of NF-κB signaling.
Chen WC; Li QL; Pan Q; Zhang HY; Fu XY; Yao F; Wang JN; Yang AK
J Exp Clin Cancer Res; 2019 Apr; 38(1):167. PubMed ID: 30995931
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
Yi T; Lee HL; Cha JH; Ko SI; Kim HJ; Shin HI; Woo KM; Ryoo HM; Kim GS; Baek JH
J Cell Physiol; 2008 Nov; 217(2):409-22. PubMed ID: 18543257
[TBL] [Abstract][Full Text] [Related]
6. High extracellular inorganic phosphate concentration inhibits RANK-RANKL signaling in osteoclast-like cells.
Mozar A; Haren N; Chasseraud M; Louvet L; Mazière C; Wattel A; Mentaverri R; Morlière P; Kamel S; Brazier M; Mazière JC; Massy ZA
J Cell Physiol; 2008 Apr; 215(1):47-54. PubMed ID: 17894387
[TBL] [Abstract][Full Text] [Related]
7. Melittin inhibits osteoclast formation through the downregulation of the RANKL-RANK signaling pathway and the inhibition of interleukin-1β in murine macrophages.
Choe JY; Kim SK
Int J Mol Med; 2017 Mar; 39(3):539-548. PubMed ID: 28204822
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling.
Kalliolias GD; Zhao B; Triantafyllopoulou A; Park-Min KH; Ivashkiv LB
Arthritis Rheum; 2010 Feb; 62(2):402-13. PubMed ID: 20112358
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 29 inhibits RANKL-induced osteoclastogenesis via activation of JNK and STAT, and inhibition of NF-κB and NFATc1.
Peng Q; Luo A; Zhou Z; Xuan W; Qiu M; Wu Q; Xu L; Kong X; Zhang M; Tan W; Xue M; Wang F
Cytokine; 2019 Jan; 113():144-154. PubMed ID: 30001863
[TBL] [Abstract][Full Text] [Related]
10. Hippuric acid and 3-(3-hydroxyphenyl) propionic acid inhibit murine osteoclastogenesis through RANKL-RANK independent pathway.
Zhao H; Lazarenko OP; Chen JR
J Cell Physiol; 2020 Jan; 235(1):599-610. PubMed ID: 31271661
[TBL] [Abstract][Full Text] [Related]
11. Fos plays an essential role in the upregulation of RANK expression in osteoclast precursors within the bone microenvironment.
Arai A; Mizoguchi T; Harada S; Kobayashi Y; Nakamichi Y; Yasuda H; Penninger JM; Yamada K; Udagawa N; Takahashi N
J Cell Sci; 2012 Jun; 125(Pt 12):2910-7. PubMed ID: 22454522
[TBL] [Abstract][Full Text] [Related]
12. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation.
Ikeda F; Nishimura R; Matsubara T; Tanaka S; Inoue J; Reddy SV; Hata K; Yamashita K; Hiraga T; Watanabe T; Kukita T; Yoshioka K; Rao A; Yoneda T
J Clin Invest; 2004 Aug; 114(4):475-84. PubMed ID: 15314684
[TBL] [Abstract][Full Text] [Related]
13. Correlating RANK ligand/RANK binding kinetics with osteoclast formation and function.
Warren JT; Zou W; Decker CE; Rohatgi N; Nelson CA; Fremont DH; Teitelbaum SL
J Cell Biochem; 2015 Nov; 116(11):2476-83. PubMed ID: 25864714
[TBL] [Abstract][Full Text] [Related]
14. Continuous Compressive Force Induces Differentiation of Osteoclasts with High Levels of Inorganic Dissolution.
Matsuike R; Nakai K; Tanaka H; Ozaki M; Kanda M; Nagasaki M; Shibata C; Mayahara K; Tanabe N; Koshi R; Nakajima A; Kawato T; Maeno M; Shimizu N; Motoyoshi M
Med Sci Monit; 2019 May; 25():3902-3909. PubMed ID: 31129676
[TBL] [Abstract][Full Text] [Related]
15. Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis.
Zhang Z; Jimi E; Bothwell AL
J Immunol; 2003 Oct; 171(7):3620-6. PubMed ID: 14500659
[TBL] [Abstract][Full Text] [Related]
16. Arctigenin suppresses receptor activator of nuclear factor κB ligand (RANKL)-mediated osteoclast differentiation in bone marrow-derived macrophages.
Kim AR; Kim HS; Lee JM; Choi JH; Kim SN; Kim DK; Kim JH; Mun SH; Kim JW; Jeon HS; Kim YM; Choi WS
Eur J Pharmacol; 2012 May; 682(1-3):29-36. PubMed ID: 22387094
[TBL] [Abstract][Full Text] [Related]
17. Receptor activator of NF-{kappa}B (RANK) cytoplasmic IVVY535-538 motif plays an essential role in tumor necrosis factor-{alpha} (TNF)-mediated osteoclastogenesis.
Jules J; Shi Z; Liu J; Xu D; Wang S; Feng X
J Biol Chem; 2010 Nov; 285(48):37427-35. PubMed ID: 20870724
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis.
Kimachi K; Kajiya H; Nakayama S; Ikebe T; Okabe K
Naunyn Schmiedebergs Arch Pharmacol; 2011 Mar; 383(3):297-308. PubMed ID: 21225243
[TBL] [Abstract][Full Text] [Related]
19. RANKL stimulates inducible nitric-oxide synthase expression and nitric oxide production in developing osteoclasts. An autocrine negative feedback mechanism triggered by RANKL-induced interferon-beta via NF-kappaB that restrains osteoclastogenesis and bone resorption.
Zheng H; Yu X; Collin-Osdoby P; Osdoby P
J Biol Chem; 2006 Jun; 281(23):15809-20. PubMed ID: 16613848
[TBL] [Abstract][Full Text] [Related]
20. Osteoclast regulation of osteoblasts via RANK‑RANKL reverse signal transduction in vitro.
Zhang S; Wang X; Li G; Chong Y; Zhang J; Guo X; Li B; Bi Z
Mol Med Rep; 2017 Oct; 16(4):3994-4000. PubMed ID: 28731168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
